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B
ackground to the debate: Coronary artery disease is 
a major cause of death worldwide. Two very different 
approaches have been proposed as a way of reducing these 
deaths. The “high risk” approach uses tools such as risk 
factor scoring and carotid ultrasound to try and identify 
those at highest risk, and then treats them aggressively. The 
“population” approach aims to shift the distribution of risk 
factors across a population in a beneﬁ  cial direction with the 
goal of reducing heart disease in the whole population.
Michael Makover’s Viewpoint: We Should Use 
High-Sensitivity Carotid Ultrasound to Detect 
Very Early Atherosclerosis and Treat Aggressively
Atherosclerotic vascular disease is the greatest cause 
of death and disability in developed countries. The best 
way to prevent these outcomes is to detect disease at the 
earliest possible stage and to attack it with pinpoint-targeted 
aggressive treatment. B-mode ultrasonography of the carotid 
artery to measure the intima-media thickness (IMT) (Figure 
1) is the most effective way to do that.
It is time to end the mindset that thinks of atherosclerosis 
as an inevitable function of aging. It is not: it is a disease, 
whether it causes an acute event or gradual decline. As with 
any disease, the earlier and more intensively we attack it—
with medications and lifestyle changes—the more successful 
we will be in containing and reversing it. Ultrasonography 
of the carotid to detect plaque and increased intimal wall 
thickness is the best, safest, and easiest early detector we have.
Patients at risk for atherosclerotic cardiovascular disease 
are identiﬁ  able only up to a point using traditional methods, 
including the Framingham risk score [1], the European 
SCORE (Systemic Coronary Risk Evaluation) [2], and the C-
reactive protein level [3]. These are particularly effective for 
people in the highest risk groups, but they have serious ﬂ  aws. 
They do not take family history of premature coronary artery 
disease into account; they do not beneﬁ  t from new assays that 
can differentiate lipoproteins by particle size and number, 
both of which are important factors in atherogenicity; 
and they do not include the quality of the patient’s diet, 
abdominal fat content, racial and ethnic genetic differences, 
confounding medical conditions, certain gender differences, 
and other factors. Thus, many patients deemed “low risk” 
for acute events within a period of time might still develop 
disease.
All of the current risk models were developed within 
the obsolete gestalt of life spans of perhaps 60 to 70 years, 
whereas people are now increasingly living productively 
into their 80s and 90s. Risk tables are based only on cardiac 
events over a relatively short time period of ten years. 
Progress in medical science is now on the steepest slope of 
exponential growth. It is reasonable to expect that those who 
maintain healthy circulation will experience good quality life 
beyond the 100-year mark in the surprisingly near future, 
and perhaps to 120 years not long after. Furthermore, risk 
escalates with age. Thus, an initial low risk proﬁ  le becomes 
far more signiﬁ  cant when considered in the context of long 
lives. Equally important, gradual impairment of blood ﬂ  ow 
that nourishes tissues can lead to peripheral vascular disease, 
increased susceptibility to infection, cognitive decline, frailty, 
and other changes that impair life quality and longevity.
While risk factors help individualize treatment, they do not 
address the most critical issue: identifying atherosclerosis at 
the very earliest stage to try to stop and reverse the process 
before any damage has occurred. Risk factors identify those 
who might develop disease. The “smoking gun” is to identify 
disease when it actually ﬁ  rst develops. Atherosclerosis begins 
as a lipid and inﬂ  ammatory cell deposition in the intimal 
subendothelial space, which expands outward, with only a 
slight inward intrusion on the lumen. This does not affect 
blood ﬂ  ow unless the lumen-side plaque cap ruptures, and a 
clot forms and expands into the blood stream. Most clots are 
limited by thrombolytic mechanisms, but signiﬁ  cant blockage 
usually results as the clot is scarred over. Some clots expand 
all the way across to the other side of the artery, completely 
occluding it, causing a heart attack or stroke [4]. 
Thus, if we could discover plaque at the very earliest stage, 
we could aggressively attack it with our full armamentarium 
of lifestyle modiﬁ  cation, addressing all the factors noted 
above, and medications—statins, ACE inhibitors, aspirin, 
niacin, ezetimibe, and others—to stabilize and then reverse 
the process before a rupture occurs. The REVERSAL trial, 
among many others, has shown that atherosclerosis is 
reversible with aggressive treatment [5]. Carotid ultrasound 
is an easy, safe, noninvasive method for detecting early, focal 
plaques and early thickening of the inner lining of the artery 
[6]. There is ample evidence that this is an effective and 
reproducible detector, and a predictor of progression and 
symptomatic disease [7]. In contrast, angiography is invasive 
and is insensitive to early changes in the artery wall thickness. 
Magnetic resonance imaging is expensive, cumbersome, and 
still experimental. Calcium scoring by computed tomography 
is less sensitive and less reproducible and suggests plaque 
presence only indirectly [8]. Angiography and calcium 
scoring entail considerable X ray exposure. 
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Figure 1. Ultrasonography of the Carotid Artery to Measure the IMT
This ﬁ  gure provides a framework for understanding the multiple, quantitative calculations undertaken for each patient’s carotid 
ultrasound scan. Two images of carotid artery without plaques (left) and two with plaques (right) are shown at the top. ROI indicates 
the region of interest in which thickness measurements are made. These were obtained from a single patient. Schematics for each 
image are provided below the video images. The grey lines indicate the measured IMT within the deﬁ  ned region of interest. Regarding 
the plaques (PL1 and PL2), M indicates maximum plaque thickness, and L indicates minimum lumen diameter at the site of maximum 
plaque thickness. Percent diameter stenosis is calculated as [M/(M + L)] × 100%. The graph (bottom) indicates length in millimeters 
on the x-axis and thickness in millimeters on the y-axis. The areas from the far wall of the left (L) and right (R) common carotid arteries 
are measured in all patients. AIMT designates the average IMT derived from the left and right measurements. PL1 and PL2 are the 
lesion lengths of the respective plaques, and M1 and M2 are the respective maximal thicknesses. APT1 and APT2 designate the respective 
average lesion thicknesses for each plaque. The total area is given by the sum of all the areas shown on the graph in units of square 
millimeters. The average total thickness (ATT) is given by the total area divided by the total length shown on the x-axis. PLn on the x-
axis is intended to indicate that the calculations are undertaken using these concepts, irrespective of the number of plaques identiﬁ  ed 
in a given study.
(Figure from [28] with permission of all four authors.)PLoS Medicine  |  www.plosmedicine.org 0274
Using high-sensitivity carotid ultrasound as a primary 
screening tool would add modest cost, but that would 
be more than offset by sharply reducing the enormous 
worldwide toll of atherosclerosis. Screening tests should be 
easy, affordable, widely available, and predictive. Carotid 
ultrasound meets all these criteria and should be used to 
screen everyone early on who is at any increased risk by 
measure of the expanded risk factors noted above.
Shah Ebrahim’s Viewpoint: Reducing Risk Factors 
across the Population Is Better Than Identifying 
Only Those at Highest Risk
The “high risk” approach to reducing heart disease 
involves identifying those at highest risk by means of risk 
factor scoring, dominated by the Framingham equations [9], 
followed by aggressive risk factor control. This approach must 
be contrasted with the “population” approach to prevention 
(Figure 2), which aims to shift the whole distribution of 
risk factors in a beneﬁ  cial direction and thereby reduce the 
incidence of cardiovascular disease in the whole population. 
In the population approach, all have to take part in making 
the population healthy but only relatively few will beneﬁ  t—
the “prevention paradox” [10]. 
Population change does require political commitment—as 
Virchow commented, “Mass diseases require mass solutions” 
[11]. There are several politically difﬁ  cult population actions 
that many public health agencies would wish to implement to 
reduce heart disease. These include extension of restrictions 
on the use and sale of tobacco products, reduction of 
“hidden” saturated fats in processed foods, and an increase 
in the opportunities for regular physical exercise. Some of 
these policies cut across the vested interests of international 
corporations that have powerful means of controlling 
elected governments, leading to a laissez-faire approach of 
emphasising individual “choice” as the means of improving 
public health [12].
Although stopping smoking and lowering blood pressure 
and blood cholesterol are beneﬁ  cial, the crucial question is 
whether using risk factor screening tools to identify people at 
high risk for disease and then treating them is more effective 
than focusing on individual risk factors. In common with 
many screening enterprises, there is only limited evidence 
to help determine whether screening for those at highest 
risk of heart disease is worthwhile. This reﬂ  ects both the 
difﬁ  culty of mounting trials of screening (which are costly, 
large scale, and of long duration) and the “culture” of 
evaluation of screening, which has been dominated by Wilson 
and Jungner’s out-dated criteria that do not emphasise the 
fundamental importance of randomised trials in evaluation 
[13]. Screening, like any other medical technology, requires 
robust evaluation [14]. 
The evidence available from randomised controlled trials 
of the high risk approach is not encouraging. The impact on 
clinical events in community populations is very limited—the 
best estimate is of no real effect at all, although an effect as 
small as a 10% risk reduction may have been missed [15].  
Since medications for reducing coronary disease morbidity 
and mortality are clearly effective, it is tempting to look 
for better screening tests for early disease, such as carotid 
ultrasound with plaque characterisation, fast computed 
tomography scanning of the coronary arteries, and genetic 
“SNPing” (looking for single nucleotide polymorphisms 
associated with coronary disease) [16]. 
But none of the new screening technologies currently 
recommended [17] have been adequately assessed in 
randomised controlled trials. Ultrasound IMT measures are 
capable of identifying people at increased risk. However, 
in evaluations of the receiver–operator curves comparing 
the accuracy of ultrasound measures with conventional risk 
factor scoring, no extra predictive power is obtained from 
ultrasound [18,19]. This is not surprising as increased IMT 
and plaque are simply the downstream consequences of 
conventional risk factors operating over many years.  
Even if screening tools were highly accurate, high risk 
approaches can never match the health gains achieved by 
small downward movements in the distribution of risk factors. 
This is because the high risk group is (by deﬁ  nition) small 
relative to the rest of the population and consequently even 
though these people are at higher relative risk, the absolute 
numbers of coronary events will always be greater in the 
much larger “low risk” population. Of course, one way around 
this problem is to deﬁ  ne the whole population as “high risk” 
and give everyone several medications (a “polypill”) to lower 
their risk [20]. 
Estimates of how much can be achieved by treating all 
those at a 15% or greater risk of suffering a cardiovascular 
event over 10 years (about half the older adult population) 
with a combination of effective drugs, show that, at best, 
only half of the events would be prevented. By contrast, 
small downward movements in blood pressure and blood 
cholesterol of 10%–15% of the mean will reduce coronary 
heart disease events by the same amount [21]. Improving the 
accuracy of risk prediction with new screening technologies 
will not alter this relationship between high risk and 
population approaches. 
If cost is factored into any policy-making process, 
it is obvious that investing in widespread use of new 
screening technologies will, inevitably, be less cost-effective 
than implementing population policies. In privatised, 
individualised, health-care systems of the United States it 
is much more likely that new screening developments will 
arise without evaluation and will prove popular with naïve, 
but worried, well people. In these circumstances, the onus is 
on the scientiﬁ  c community to demand better standards of 
evidence, as many governments will not.
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Figure 2. The High Risk Versus the Population Approach to Prevention 
(Figure: John Emberson)PLoS Medicine  |  www.plosmedicine.org 0275
Makover’s Response to Ebrahim’s Viewpoint
While the “population” approach is obviously very 
important, there is no reason not to use the “high risk” 
approach as well. “High risk” is the wrong term—all 
arteries matter over a 120-year life span. We must attack 
atherosclerosis at the very onset, not wait until it is “high risk.”   
All previous approaches were designed to detect those at 
allegedly higher risk by various criteria. This misses the point. 
Once plaque exists, risk exists, especially when viewed over a 
full lifetime, not the current ten-year standard. And although 
the aggressive approach I outlined in my viewpoint would 
obviously have a cost, the savings (a reduction in the ﬁ  nancial 
toll of cardiovascular disease) would be greater than the cost. 
Ultrasonography of the carotid artery intimal wall is 
effective and highly predictive according to the great 
preponderance of studies [8]. Ebrahim cites two studies to 
support his argument that measuring carotid IMT offers no 
additional predictive power over conventional screening 
tools [18,19], but the ﬁ  rst of these has serious ﬂ  aws (such 
as a signiﬁ  cant dropout rate that the authors assumed was 
random, a short follow-up period, and the inclusion only of 
people of an advanced age) [18], and the other concluded 
that carotid IMT measurement “substantially improved 
prediction of future coronary heart disease” [19].
Millions of people are at risk now and cannot wait for 
endless studies to prove over and over what we already know. 
It is not “naïve” for well people to want to remain well and 
to maintain their arteries to enable healthy older lives. Nor 
should we disparage as “worried” the very human desire to 
remain that way. Population-wide planning is important, but 
doctors take care of each patient as an individual. Carotid 
ultrasonography is by far the best way to design treatment 
for every patient exactly as needed. I believe that there is 
already sufﬁ  cient evidence and sensible rationale to meld 
already well-proven technologies and approaches into a 
comprehensive, aggressive attack on atherosclerosis.
Ebrahim’s Response to Makover’s Viewpoint
Declines in the risk of coronary heart disease have 
been reported in many countries that had experienced 
cardiovascular disease “epidemics” during the middle of 
the 20th century [22]. The onset of these beneﬁ  cial trends 
pre-dated the introduction of both risk factor screening 
and widespread use of effective treatment of hypertension 
and hypercholesterolaemia. These downward trends in 
cardiovascular mortality have contributed to increases in life 
expectancy.
In autopsies done during the Korean and Vietnam 
wars, atherosclerosis was found in 77% and 45% of young 
men, respectively [23,24]. More recently, the origins of 
cardiovascular disease have been pushed back to fetal 
development and early childhood [25,26]. Raised levels of 
risk factors are set in early life, and if earlier intervention 
means better outcomes, it is at this stage (i.e., in early life) 
that treatment and prevention must be targeted. 
Plaques are remarkably common in middle-aged people 
screened using ultrasound [27], but most are stable and 
unlikely to rupture. Presence of plaque in otherwise healthy 
people does not identify those who are destined to suffer 
an event or beneﬁ  t from treatment. In the same way as risk 
factors provide a probabilistic evaluation of the chances of 
suffering a clinical event, so too does presence of plaque, with 
no greater accuracy than risk factor scoring methods [19].
Using carotid ultrasound screening to deﬁ  ne a subgroup of 
those with plaque but normal or low levels of cardiovascular 
risk factors may be useful (see Table 1). However, studies 
have yet to be done to conﬁ  rm whether plaque, in the 
absence of raised risk factors, is harmful. Importantly, trials 
are needed to determine whether treating such people 
aggressively—lowering their already low risk factors—results 
in better outcomes. It is possible that imaging of arteries may 
provide extra psychological incentives for patient adherence 
to lifestyle and drug regimens, but this too remains to be 
tested in well-designed randomised trials.
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